Opinion

Video

Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Author(s):

Sara M. Tolaney, MD, MPH

Patients with metastatic breast cancer receiving HER2-targeted therapies should promptly report any respiratory symptoms or signs of lung and heart disease to their oncology care team to facilitate early intervention and management of side effects.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Photo of Hideko Warner
Picture of LaShae D. Rolle
Photo of Jake Messier
Related Content
Image of women with text.
August 15th 2025

Breast Cancer Survivor Shares Benefits of Strength Training on Chemo

Ryan Scott
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
August 15th 2025

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, review date: © stock.adobe.com.
August 15th 2025

FDA Accepts NDA for Vepdegestrant in ESR1+ Advanced Breast Cancer

Spencer Feldman
Cancer Horizons podcast logo
August 15th 2025

Conference Highlights from SABCS

Alex Biese Brielle Benyon
Certain gut bacteria were linked to higher risk of heart damage in older patients with breast cancer: © stock.adobe.com.
August 15th 2025

Gut Bacteria May Help Predict Heart Risks in Breast Cancer Treatment

Spencer Feldman
Laura Yeager is a two-time breast cancer survivor. Catch up on all of Laura's blogs here!
August 15th 2025

A Moment of Kindness I’ll Never Forget During Cancer Treatment

Laura Yeager